作者: A. Warth , A. Stenzinger , W. Weichert
DOI: 10.1007/S00292-013-1787-9
关键词:
摘要: In recent years the classification of pulmonary cancer has seen a paradigm shift with respect to both morphological as well molecular aspects. On side this includes novel criteria for tumor from biopsy material based on and immunohistochemical aspects patterns adenocarcinomas. addition, new now adenocarcinoma in situ minimally invasive entities variety subtypes. This reclassification was accompanied complemented by tremendous developments field lung genomics which paved way widely established predictive markers, e.g. epidermal growth factor receptor (EGFR) mutations EML4-ALK translocations will certainly lead markers not only but also other neoplasms.